TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

TP53 mutation is known to be a poor prognostic factor in many hematologic malignancies, but it is not included in any Myelofibrosis-specific prognostic score. Recently, studies have shown that TP53 mutation may negatively impact the outcomes of patients with Myelofibrosis, including those undergoing hematopoietic stem cell transplantation. In this study, we aimed to analyze the impact of TP53 mutation on the overall survival and leukemia-free survival of patients with chronic-phase Myelofibrosis, regardless of whether they had undergone transplantation. A total of 250 patients were included in the study, of whom 9 (3.2%) harbored a TP53 mutation, including six (3.2%) among non-HSCT patients and three (3.1%) among HSCT patients. In both groups, the presence of TP53 mutation correlated with shorter overall survival, while in non-HSCT patients, it also correlated with lower leukemia-free survival. Moreover, we provide a meta-analysis on the role of TP53 mutation in patients with chronic-phase Myelofibrosis, confirming its negative prognostic impact on overall survival.